Patients with adenoid cystic carcinoma (ACC) have waited decades for a treatment option. At Remix Therapeutics, we intend to change that. We are a clinical-stage biopharmaceutical company that has pioneered a new class of small molecule medicines targeting the RNA splicing machinery - correcting the disease-causing errors that drive ACC and other serious conditions at their source. REM-422 is our lead program and our near-term focus. In addition to ACC REM-422 is currently being evaluated as a treatment for AML/HR-MDS with aspirations to evolve into other oncology indications with high unmet need. REM-422 is at a critical inflection point in its clinical development, and Remix is building the team to bring this novel molecule forward as a medicine for patients
Position Summary:
Remix is seeking a Senior Director, Clinical Operations to lead our clinical operations function at a pivotal moment for REM-422 and the ACC patients we serve. Reporting to the SVP, Clinical Development Operations & Patient Advocacy you will drive operational execution, mentor and develop a team, and work at the intersection of science and execution to bring a potential first-in-class therapy across the finish line.
Key Responsibilities:
Qualifications:
Salary Range
$230,000 - $281,000 USD
This range reflects the expected base salary for this position, plus bonus, equity, and benefits as applicable. Actual salaries may vary based on factors, such as skill, experience, and qualification for the role.